NCT06604169

Brief Summary

  1. 1.To observe the failure rate of S-ICD screening in HCM patients at high risk of SCD.
  2. 2.To observe the incidence of IAS in HCM patients with S-ICD implantation and explore the related factors of IAS.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
589

participants targeted

Target at P75+ for all trials

Timeline
27mo left

Started Aug 2024

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress44%
Aug 2024Jul 2028

Study Start

First participant enrolled

August 1, 2024

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

September 18, 2024

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 19, 2024

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2028

Last Updated

September 19, 2024

Status Verified

September 1, 2024

Enrollment Period

3 years

First QC Date

September 18, 2024

Last Update Submit

September 18, 2024

Conditions

Keywords

HCMS-ICD

Outcome Measures

Primary Outcomes (2)

  • the failure rate of S-ICD screening

    S-ICD screening failed

    3 months

  • The inappropriate shock event

    The incidence of inappropriate shock event

    3 months

Eligibility Criteria

Age14 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study was a multicenter, prospective, observational study that prospectively included HCM patients assessed as meeting the ICD implantation indication at Fuwai Hospital and National Collaborative Hospitals from July 1, 2024 to June 30, 2027.

You may qualify if:

  • HCM patients assessed as meeting the ICD implantation indication

You may not qualify if:

  • Combined with bradycardia with pacing indications;
  • Frequent monomorphic ventricular tachycardia require ATP therapy;
  • With indications of CRT;
  • Combined with other diseases, life expectancy is less than 1 year.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fuwai hospital

Beijing, China, 100037, China

Location

MeSH Terms

Conditions

Cardiomyopathy, Hypertrophic

Condition Hierarchy (Ancestors)

CardiomyopathiesHeart DiseasesCardiovascular DiseasesAortic Stenosis, SubvalvularAortic Valve StenosisAortic Valve DiseaseHeart Valve Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 18, 2024

First Posted

September 19, 2024

Study Start

August 1, 2024

Primary Completion (Estimated)

July 31, 2027

Study Completion (Estimated)

July 31, 2028

Last Updated

September 19, 2024

Record last verified: 2024-09

Locations